Copertina

The Addition of Concurrent Immune Checkpoint Inhibitors for Chemoradiotherapy With Consolidative Immune Checkpoint Inhibitors in Unresectable Cancers: A Systematic Review and Meta‐Analysis

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Xu Tong, Zhenting Liu, Xiaoxiang Zhou, Nan Bi, Yibo Gao
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	International Journal of Cancer
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Targeting HIF as a Promising Approach to Synergize With Immune Checkpoint Inhibitors
di: Shuai Li, et al.
Pubblicazione: (2026)

Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors
di: Wenke Li, et al.
Pubblicazione: (2025)

Efficacy and Safety of Immune Checkpoint Inhibitors in the Treatment of Hematologic Malignancies: An Umbrella Review of Systematic Reviews and Meta‐Analyses
di: Zhengyu Yu, et al.
Pubblicazione: (2026)

Immune Checkpoint Inhibitors +/− Chemotherapy for Patients With NSCLC and Brain Metastases: A Systematic Review and Network Meta‐Analysis
di: Lauren Julia Brown, et al.
Pubblicazione: (2025)

Prognostic Potential of Baseline Eosinophils at the Initiation of Immune Checkpoint Inhibitor Treatment of Metastatic Melanoma: A Systematic Review and Meta‐Analysis
di: Thilo Gambichler, et al.
Pubblicazione: (2025)

Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study
di: Ling Chen, et al.
Pubblicazione: (2024)

Concomitant Usage of H1‐Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient Survival
di: Yin Leung, et al.
Pubblicazione: (2025)

Rethinking Invasive Mediastinal Staging in the Era of Neoadjuvant Immune‐Checkpoint Inhibitors
di: Saulo Brito Silva, et al.
Pubblicazione: (2026)

Efficacy and Safety of Combination Therapy With Immune Checkpoint Inhibitors and Chemotherapy With Gemcitabine and Nab‐Paclitaxel in Pancreatic Cancer: A Systematic Review
di: Hanye Sohrabi, et al.
Pubblicazione: (2026)

Mutation in CDC42 Gene Set as a Response Biomarker for Immune Checkpoint Inhibitor Therapy
di: Kun Wang, et al.
Pubblicazione: (2025)

Plasma Fibrinogen Predicts Response to Immune Checkpoint Inhibitor by Inflammatory Tumor Microenvironment in Esophageal Cancer
di: Keiso Ho, et al.
Pubblicazione: (2026)

Immune‐Related Adverse Events in Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors: Insights From a FAERS Disproportionality Analysis
di: Pooja Gokhale, et al.
Pubblicazione: (2026)

Current Knowledge of Immune Checkpoint Inhibitor‐Induced Thrombocytopenia: Epidemiology, Mechanisms, and Management
di: Youran Dai, et al.
Pubblicazione: (2026)

Low‐Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma
di: Rong Li, et al.
Pubblicazione: (2025)

Monotherapy With Immune Checkpoint Inhibitors in Patients With Recurrent and/or Metastatic Sinonasal Squamous Cell Carcinoma
di: Alexander Lein, et al.
Pubblicazione: (2025)

Low‐Level Viremia Reduces Immune Checkpoint Inhibitor Efficacy in Unresectable HCC: Key Considerations
di: Yihang Xie
Pubblicazione: (2025)

Association of Immune‐Related Adverse Events and the Efficacy of Immune Checkpoint Inhibitors in Non‐Small Cell Lung Cancer: Adjusting for Immortal Time Bias
di: Yoshiki Kuwabara, et al.
Pubblicazione: (2026)

Peripheral Immune Cell Profiles as Predictive Biomarkers of Immune Checkpoint Inhibitor Efficacy in Elderly Patients With Advanced Non‐Small Cell Lung Cancer
di: Shouzheng Wang, et al.
Pubblicazione: (2025)

Associations Between Pre‐Existing Cardiovascular Disease and Survival in Patients on Immune Checkpoint Inhibitor Therapy
di: Aditya Mahadevan, et al.
Pubblicazione: (2025)

The Efficacy and Safety of Brain Radiotherapy Combined With Immune Checkpoint Inhibitors (ICIs) for Small‐Cell Lung Cancer (SCLC) Patients With Brain Metastases (BMs)
di: Jie Xu, et al.
Pubblicazione: (2025)

Hepatobiliary Adverse Events Linked to Immune Checkpoint Inhibitors: A Real‐World Pharmacovigilance Analysis Using FAERS Data
di: Yuzhu Chen, et al.
Pubblicazione: (2025)

TGFβ1 and SMAD3 Expression Are Associated With Survival After the Immune Checkpoint Inhibitor Therapy for Small Cell Lung Cancer
di: Zenta Seto, et al.
Pubblicazione: (2025)

Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence
di: Yuta Yamanaka, et al.
Pubblicazione: (2024)

Immune Checkpoint Inhibitor‐Based Therapy as the First‐Line Treatment for Advanced Non‐Small Cell Lung Cancer: Efficacy, Challenges, and Future Perspectives
di: Xingxiang Pu, et al.
Pubblicazione: (2025)

An Anoikis Resistance Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Blockades in Gastric Cancer
di: Xing Cai, et al.
Pubblicazione: (2026)

A Disproportionality Analysis of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Agents Using the FDA Adverse Event Reporting System Database
di: Boyi Liu, et al.
Pubblicazione: (2026)

Autoimmune Bullous Diseases Associated With Immune Checkpoint Inhibitors: An Analysis Based on a Systematic Review
di: Min Zou, et al.
Pubblicazione: (2026)

Predictive Value of Neutrophil‐to‐Lymphocyte Ratio for Immune Checkpoint Inhibitor‐Related Myocarditis Among Patients Treated for Non‐Small‐Cell Lung Cancer
di: Jian Xue, et al.
Pubblicazione: (2025)

Topical Ruxolitinib for Immune Checkpoint Inhibitor–Induced Vitiligo
di: Federico Venturi, et al.
Pubblicazione: (2026)

Durable Responses With Immune Checkpoint Inhibitors in the DANUBE Trial
di: Ryunosuke Nakagawa, et al.
Pubblicazione: (2025)

The Efficacy of Immune Checkpoint Inhibitors in the EGFR Mutant and Wild‐Type Non‐Small Cell Lung Cancer Is Positively Associated With the Maturation and Abundance of Dendritic Cells
di: Fengqi Xiao, et al.
Pubblicazione: (2025)

A Fatal Case of Immune Checkpoint Inhibitor‐Mediated Myasthenia Gravis, Myositis, and Cardiomyopathy Overlap Syndrome in Urothelial Carcinoma
di: Matthew T. Newman, et al.
Pubblicazione: (2024)

The Black Hole of Immune Checkpoint Blocking Therapy for Gastric Cancer: Hyperprogressive Disease
di: Zhuan‐Fang Wang, et al.
Pubblicazione: (2025)

Comparison of the Immune Checkpoint Inhibitor‐Free Survival Between Patients Who Completed and Those Who Discontinued ICI for Non‐Small Cell Lung Cancer
di: Takahiro Nagai, et al.
Pubblicazione: (2025)

Bridging FDA Adverse Event Reporting System ( FAERS ) and Clinical Practice: Comprehensive Characterization of Immune Checkpoint Inhibitors Toxicities in Geriatric Lung Cancer Patients
di: Yumeng Tian, et al.
Pubblicazione: (2026)

A Case Report of Promising Response to Combination Therapy With an Immune Checkpoint Inhibitor (Pembrolizumab) and Multi‐Targeted Tyrosine Kinase Inhibitor (Pazopanib) in Metastatic De‐Differentiated Chondrosarcoma
di: Matthew Youssef, et al.
Pubblicazione: (2026)

Application of Immune Checkpoint Inhibitors in Cancer
di: Zhijun Chen, et al.
Pubblicazione: (2025)

Successful Identification and Treatment of Cancer of Unknown Primary Originating From Gastric Cancer Using Comprehensive Genomic Profiling and Immune Checkpoint Inhibitor Therapy: A Case Report
di: Takahiro Sasaki, et al.
Pubblicazione: (2025)

Successful Management of Suspected Epstein–Barr Virus‐Associated Hemophagocytic Lymphohistiocytosis in BRAF ‐Mutant Cholangiocarcinoma Following Treatment With Immune Checkpoint Inhibitors and BRAF / MEK Inhibitors: A Case Report
di: Akira Shibata, et al.
Pubblicazione: (2026)

Real‐World Evidence That Non‐Smokers With High PD‐L1 Non‐Squamous NSCLC Have Poorer Outcomes With Immune Checkpoint Inhibitors
di: Yu‐Chu Kuo, et al.
Pubblicazione: (2025)